Compare MMYT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | ARQT |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2010 | 2020 |
| Metric | MMYT | ARQT |
|---|---|---|
| Price | $40.23 | $23.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $106.33 | $34.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $17.55 | $34.46 |
| Revenue Next Year | $17.65 | $29.77 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $32.67 | $11.86 |
| 52 Week High | $113.85 | $31.77 |
| Indicator | MMYT | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 47.78 |
| Support Level | $32.67 | $22.56 |
| Resistance Level | $103.66 | $23.46 |
| Average True Range (ATR) | 2.83 | 0.95 |
| MACD | 0.62 | 0.28 |
| Stochastic Oscillator | 51.34 | 61.18 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.